STOCKS | uniQure Shares Surge After FDA Allows Huntington’s Gene Therapy Filing Without New Study
2026-06-17 14:33:24
uniQure NV shares soared after the company said it can seek US approval for its Huntington’s disease gene therapy before conducting a new study. According to Bloomberg, the reversal suggests the Trump administration is easing its earlier hard-line stance on drug reviews.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
